MorphoSys (NASDAQ:MOR) Shares Gap Down to $4.01

MorphoSys AG (NASDAQ:MORGet Rating)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $4.01, but opened at $3.89. MorphoSys shares last traded at $3.89, with a volume of 254 shares.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on MOR shares. Deutsche Bank Aktiengesellschaft lowered MorphoSys from a “hold” rating to a “sell” rating in a research note on Monday, October 24th. Stifel Nicolaus lowered MorphoSys from a “buy” rating to a “hold” rating in a research note on Tuesday, November 15th. JMP Securities cut their price objective on MorphoSys from $32.00 to $15.00 and set a “market outperform” rating for the company in a research note on Friday, November 18th. Citigroup lowered MorphoSys from a “neutral” rating to a “sell” rating in a research note on Tuesday, November 15th. Finally, Morgan Stanley boosted their price objective on MorphoSys from €26.00 ($26.53) to €28.00 ($28.57) and gave the stock an “equal weight” rating in a research note on Friday, July 29th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $26.00.

MorphoSys Stock Up 3.1 %

The company has a quick ratio of 2.91, a current ratio of 2.98 and a debt-to-equity ratio of 2.01. The business has a 50-day moving average price of $4.91 and a 200-day moving average price of $5.06. The firm has a market capitalization of $547.71 million, a PE ratio of -0.57 and a beta of 0.99.

MorphoSys (NASDAQ:MORGet Rating) last posted its quarterly earnings results on Wednesday, November 16th. The company reported ($0.91) earnings per share (EPS) for the quarter. The company had revenue of $96.56 million during the quarter. MorphoSys had a negative net margin of 357.89% and a negative return on equity of 688.39%. During the same period in the previous year, the business earned ($0.97) EPS. Equities research analysts forecast that MorphoSys AG will post -2.39 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MorphoSys

A number of large investors have recently made changes to their positions in MOR. UBS Group AG lifted its holdings in MorphoSys by 122.7% in the third quarter. UBS Group AG now owns 5,141 shares of the company’s stock valued at $26,000 after acquiring an additional 2,832 shares during the last quarter. Virtu Financial LLC acquired a new position in MorphoSys in the second quarter valued at approximately $53,000. Citadel Advisors LLC acquired a new position in MorphoSys in the third quarter valued at approximately $101,000. Capricorn Fund Managers Ltd acquired a new position in MorphoSys in the first quarter valued at approximately $177,000. Finally, OLD Mission Capital LLC acquired a new position in MorphoSys in the second quarter valued at approximately $195,000. 1.82% of the stock is currently owned by hedge funds and other institutional investors.

About MorphoSys

(Get Rating)

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Featured Stories

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.